Cross-Sector entity
Amgen is most often covered alongside FDA, which appears in 4 of these 14 stories. That works out to roughly 0.6 stories per week across a 166-day span. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 4 of those 14, with the remainder spread across 5 other categories.
14 verified stories tracked
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 21 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Amgen is most often covered alongside FDA, which appears in 4 of these 14 stories. That works out to roughly 0.6 stories per week across a 166-day span. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 4 of those 14, with the remainder spread across 5 other categories. Each carries 22.1 original sources on average. Amgen appears in 14 tracked Cross-Sector stories published from February 22, 2026 through August 6, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 14 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amgen. Shared-story counts are live from our verified record — not editorial picks.
SpaceX Post-IPO Lock-Up Expiry Begins
The expiration of the lock-up period for SpaceX’s recently public shares is expected to increase potential selling pressure.
Dow Clinches New Record; Tech Slumps
The Dow rose 0.49% to 54,349.06. The S&P 500 dipped 0.17%. The Nasdaq fell 0.83% as SpaceX and AMD shares tumbled after earnings. Amgen and Disney led the Dow.
Dow and S&P 500 Set Records
Both indexes closed at all-time highs on Tuesday as oil prices and U.S. Treasury yields dropped on hopes of a Middle East peace deal, easing inflation and rate-hike fears.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Q4 2025 Preview
Analysts set expectations for oncology-driven revenue growth.
Loqtorzi Launch
Full commercial ramp-up of the first-in-class PD-1 for NPC.
Yusimry Divestiture
Sale of adalimumab biosimilar to HK King-Friend for $40M.
Cimerli Divestiture
Coherus sells its ranibizumab biosimilar to Sandoz for $170M.
The Dow Jones Industrial Average closed at a record 54,349.06 on August 5, buoyed by a potential Iran-Oman peace deal that eased rate-hike fears. In contrast, the Nasdaq fell 0.8% as SpaceX’s 13.6% post-earnings plunge and an AMD drop underscored mounting skepticism about sustained AI spending.
Source: freemalaysiatoday.com · businesstimes.com.sg
Oscar Health's use of a copay accumulator program has drawn attention to how insurers manage medical loss ratios. By not counting manufacturer assistance, insurers keep claims low, but regulatory and reputational risks could affect investor outlook.
Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care.
Drugmaker copay assistance programs are meant to lower barriers to high-cost specialty drugs, but accumulator programs circumvent them. For Amgen and other pharma companies, this practice threatens patient adherence and undermines the value of patient support initiatives.
Source: mcall.com · journal-advocate.com
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition.
Source: Connor Mycroft (cn) · Connor Mycroft (hk)
Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Source: kingstonthisweek.com · shorelinebeacon.com
A growing movement in cardiovascular care is challenging the 'prescribe-first' mentality of statin therapy, emphasizing patient autonomy and shared decision-making. As clinical guidelines evolve, the healthcare industry is grappling with how to balance standardized protocols with individualized patient preferences and risk profiles.
Source: theobserver.ca · clintonnewsrecord.com
